openPR Logo
Press release

Global Spiramycin Base (Spiramycin) (CAS 8025-81-8) Market Outlook 2016-2021 – Market Research HUB

03-30-2017 11:18 AM CET | Health & Medicine

Press release from: Market Research Reports MRH

Pharmaceutical Industry

Pharmaceutical Industry

Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Global Spiramycin Base (Spiramycin) (CAS 8025-81-8) Market Outlook 2016-2021” This study offers professional analysis of the current state of Spiramycin Base (Spiramycin) (CAS 8025-81-8) Market.

Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=835337

Spiramycin is a macrolide antibiotic and antiparasitic It is used to treat toxoplasmosis and various other infections of soft tissues. Although used in Europe, Canada and Mexico, spiramycin is still considered an experimental drug in the United States, but can sometimes be obtained by special permission from the FDA for toxoplasmosis in the first trimester of pregnancy.

Spiramycin has been used in Europe since the year 2000 under the trade name "Rovamycine", produced by Rhone-Poulenc Rorer and Famar Lyon, France and Eczacibasi Ilae, Turkey. It also goes under the name Rovamycine in Canada (distributed by OdanLaboratories), where it is mostly marketed to dentists for mouth infections.

Spiramycin is a 16-membered ring macrolide. It was discovered in 1952 as a product of Streptomyces ambofaciens. As a preparation for oral administration it has been used since 1955, in 1987 also the parenteral form was introduced into practice. The antibiotic action involves inhibition of protein synthesis in the bacterial cell during translocation. Resistance to spiramycin can develop by several mechanisms and its prevalence is to a considerable extent proportional to the frequency of prescription in a given area. The antibacterial spectrum comprises Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium species.

Enterobacteria, pseudomonads and pathogenic moulds are resistant. Its action is mainly bacteriostatic, on highly sensitive strains it exerts a bactericide action. As compared with erythromycin, it is in vitro weight for weight 5 to 20 less effective, an equipotential therapeutic dose is, however, only double. This difference between the effectiveness in vitro and in vivo is explained above all by the great affinity of spiramycin to tissues where it achieves concentrations many times higher than serum levels. An important part is played also by the slow release of the antibiotic from the tissue compartment, the marked action on microbes in sub-inhibition concentrations and the relatively long persisting post-antibiotic effect. Its great advantage is the exceptionally favourable tolerance-gastrointestinal and general. It is available for parenteral and oral administration

This report provides detailed analysis of worldwide markets for Spiramycin Base (Spiramycin) (CAS 8025-81-8) from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and subsectors. It covers the key technological and market trends in the Spiramycin Base (Spiramycin) (CAS 8025-81-8) market and further lays out an analysis of the factors influencing the supply/demand for Spiramycin Base (Spiramycin) (CAS 8025-81-8), and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.

GCCs report, Global Spiramycin Base (Spiramycin) (CAS 8025-81-8) Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Spiramycin Base (Spiramycin) (CAS 8025-81-8) market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Spiramycin Base (Spiramycin) (CAS 8025-81-8) market are Sanofi-Aventis (France), CLL Pharma (Italy), TOPFOND (China), Fortune Pharmaceutical (China), among others.

Read Full Report with TOC@ http://www.marketresearchhub.com/report/global-spiramycin-base-spiramycin-cas-8025-81-8-market-outlook-2016-2021-report.html

The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Spiramycin Base (Spiramycin) (CAS 8025-81-8) industry has been provided.

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of Market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Follow Us on:
LinkedIn: https://www.linkedin.com/company/market-research-hub
Facebook: https://www.facebook.com/MarketResearchHub/
Twitter: https://twitter.com/MktResearchHub

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Spiramycin Base (Spiramycin) (CAS 8025-81-8) Market Outlook 2016-2021 – Market Research HUB here

News-ID: 486388 • Views:

More Releases from Market Research Reports MRH

Global In-Flight Catering Services Market Projected to Display a Robust Growth With a CAGR of 5.35% during 2017 – 2022
Global In-Flight Catering Services Market Projected to Display a Robust Growth W …
The report titled “Global In-Flight Catering Services Market: Analysis By Segment (In-house, Outsource, Hotels, Small Caterers), By Flight Type (Low Cost, Full Service, Private Aircraft), By Region, By Country: Opportunities and Forecast (2017-2022)” has covered and analyzed the potential of Global Inflight Catering Service Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help
Global Clothing Accessory Market to Gain Steady Growth until 2021 Due to Rising Spending Patterns of Consumers
Global Clothing Accessory Market to Gain Steady Growth until 2021 Due to Rising …
The dynamics of the apparel industry are changing dramatically. As per a recent research report, apparel accessories became a major profit earner in 2016 for many fashion companies. Many fashion houses have begun to shift the focus to accessories on ready-to-wear items. To analyze the market current scenario and future growth prospects, a study titled “Global Clothing Accessory Market to 2021” has been published to the online repository of Market
Global Fortifying Agents Sales Market Report 2017: Market Outlook & Deep Study of Top Consumers, Players and Strategies
Global Fortifying Agents Sales Market Report 2017: Market Outlook & Deep Study o …
The report on Fortifying Agents Sales Market is the latest addition to the huge database of Market Research HUIB. This research study is segmented on the basis of applications, technology, geography, and types. The Report provides a detailed Fortifying Agents Sales Industry overview along with the analysis of industry’s gross margin, cost structure, consumption value, and sale price. The leading companies of the Fortifying Agents Sales Market, manufacturers, and distributors
Acyl CoA Desaturase Therapeutics & Development Stages Covered under Pipeline Review, H1 2017
Acyl CoA Desaturase Therapeutics & Development Stages Covered under Pipeline Rev …
Use of acyl-CoA desaturase for maintaining structure and function of membranes within the cells of the organism acts as the reason for its wide use. To detail the pipeline overview, Market Research Hub (MRH) has reported a new report focusing on acyl-CoA desaturase in the research study titled as “Acyl-CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl-CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H1

All 5 Releases


More Releases for Spiramycin

Spiramycin Base Market Size, Geography Trends And Analysis of Leading Market Pla …
LOS ANGELES, United States:  - The global Spiramycin Base market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Spiramycin Base market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and
Large Macrolide Drugs Market Increased Demand Expected to Soar Revenue during Fo …
Large macrolide drugs are used in the treatment of respiratory diseases caused by gram positive bacteria and gram negative bacteria. Large macrolide drugs include clarithromycin, azithromycin, erythromycin and others. Large macrolide drugs are very popular due to their efficiency and safety. Large macrolide drugs have a large lactone ring containing 12 to 14 atoms. Large Macrolide Drugs Market inhibit the bacterial protein synthesis by interrupting the ribosome functioning. Clarithromycin and
Expansion of Toxoplasmosis Infection Treatment Market to Remain Consistent Durin …
Toxoplasmosis caused by a single celled parasite called “Toxoplasma gondii”, which results in an infection usually occurs by raw or undercooked contaminated meat particularly lamb or pork, drinking contaminated water and milk from an infected goat, exposure from cat feces, mother to child transmission during pregnancy and organs transplantation in rare cases. Toxoplasmosis Infections causes flu like symptoms including muscle ache, body ache, fever, headache, sore throat, fatigue, swollen lymph nodes
Global Spiramycin Base (Spiramycin) (CAS 8025-81-8) Market Outlook 2016-2021
Spiramycin is a macrolide antibiotic and antiparasitic It is used to treat toxoplasmosis and various other infections of soft tissues. Although used in Europe, Canada and Mexico, spiramycin is still considered an experimental drug in the United States, but can sometimes be obtained by special permission from the FDA for toxoplasmosis in the first trimester of pregnancy. Spiramycin has been used in Europe since the year 2000 under the trade name
Global Spiramycin Base (Spiramycin) (CAS 8025-81-8) Market 2016 - Sanofi-Aventis …
Spiramycin is a macrolide antibiotic and antiparasitic It is used to treat toxoplasmosis and various other infections of soft tissues. Although used in Europe, Canada and Mexico, spiramycin is still considered an experimental drug in the United States, but can sometimes be obtained by special permission from the FDA for toxoplasmosis in the first trimester of pregnancy. Spiramycin has been used in Europe since the year 2000 under the trade name
Global Spiramycin Base (Spiramycin) (CAS 8025-81-8) Market Share Forecast by App …
Big Market Research adds “Global Spiramycin Base (Spiramycin) Software Market” new report to its research. The report spread across 100 pages with table and figures in it. About Spiramycin Base (Spiramycin) Spiramycin is a macrolide antibiotic and antiparasitic It is used to treat toxoplasmosis and various other infections of soft tissues. Although used in Europe, Canada and Mexico, spiramycin is still considered an experimental drug in the United States, but can